top of page

Peer-reviewed Publications
about Hope Bio's therapeutics

Hope Biosciences is privileged to see our cellular therapeutics at work in U.S. Food and Drug Administration (F.D.A.) - authorized research in academic, hospital, and independent clinical research organization settings throughout the United States. The publications showcased here reflect continued commitment to the most rigorous research standards.

May 2026

Access required

brain injury

"Autologous adipose-derived mesenchymal stromal cells for chronic traumatic brain injury"

​

​​

​

Oxford Academic​, Brain

doi: 10.1093/brain/awag165

Read Abstract
Visit Source
Visit Source
Visit Source

May 2026

Open Source

Parkinson's disease

"Evaluation of Multiple Intravenous Infusions of Autologous Adipose-Derived Mesenchymal Stem Cells in Parkinson’s Disease: A Randomized, Double-Blind Clinical Trial"

 

Wiley's​, Parkinson's Disease

doi: 10.1155/padi/9934417

Access pdf
Visit Source
Visit Source
Visit Source

October 2024

Open Source

Parkinson's disease

"Safety and efficacy of adipose-derived mesenchymal stem cell therapy in elderly Parkinson's disease patients: an intermediate-size expanded access program"

 

Elsevier​, Cytotherapy

doi: 10.1016/j.jcyt.2024.09.004

Access pdf
Visit Source
Visit Source
Visit Source

December 2023

Open Source

COVID-19

"Safety of multiple intravenous infusions of adipose-derived mesenchymal stem cells for hospitalized cases of COVID-19: a randomized controlled trial"

​

Frontiers, Frontiers in Medicine

doi: 10.3389/fmed.2023.1321303

Access pdf
Visit Source
Visit Source
Visit Source

December 2023

Open Source

Spinal cord injury

"Functional recovery of a 41-year-old quadriplegic spinal cord injury patient following multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells: a case report"​

​

Frontiers, Frontiers in Transplantation

doi: 10.3389/frtra.2023.1287508

Access pdf
Visit Source
Visit Source
Visit Source

October 2023

Open Source

"Long haul" COVID-19

"Adipose-derived, autologous mesenchymal stem cell therapy for patients with post-COVID-19 syndrome: an intermediate-size expanded access program"​

​

BMC, Stem Cell Research & Therapy

doi: 10.1186/s13287-023-03522-1

Access pdf
Visit Source
Visit Source
Visit Source

September 2023

Open Source

Parkinson's Disease

"Long-term, repeated doses of intravenous autologous mesenchymal stem cells for a patient with Parkinson's disease: a case report"​

​

Frontiers, Frontiers in Neurology 

doi: 10.3389/fneur.2023.1257080

​

Access pdf
Visit Source
Visit Source
Visit Source

March 2023

Open Source

Cerebral palsy

"Multi-Dose Hope Biosciences-Adipose-Derived Mesenchymal Stem Cell (HB-adMSC) Therapy for a Patient with Cerebral Palsy: A Case Report"

​

ClinMed International Library, International Journal of Stem Cell Research & Therapy

doi: 10.23937/2469-570X/1410078

Access pdf
Visit Source
Visit Source
Visit Source

September 2022

Open Source

Lupus

"Frequency-dependent effect of intravenous administration of human adipose-derived mesenchymal stem cell therapy for severe Systemic Lupus Erythematosus: A case report"

​​

Elsevier, Journal of Translational Autoimmunity

doi: 10.1016/j.jtauto.2022.100166

Access pdf
Visit Source
Visit Source
Visit Source

March 2022

Open Source

Rheumatoid Arthritis

"Safety and efficacy of autologous, adipose-derived mesenchymal stem cells in patients with rheumatoid arthritis: a phase I/IIa, open-label, non-randomized pilot trial"

​

BMC, Stem Cell Research & Therapy

doi: 10.1186/s13287-022-02763-w

Access pdf
Visit Source
Visit Source
Visit Source

November 2019

Open Source

Traumatic brain injury (TBI)

"Human adipose-derived mesenchymal stem
cells for acute and sub-acute TBI"

​

PloS ONE

doi: 10.1371/journal.pone.0233263

Access pdf
Visit Source
Visit Source
Visit Source

Want more reading?​

bottom of page